1 Min Read
May 23 (Reuters) -
* CLJI worldwide trial enrolls first patient in clinical study evaluating the performance of viblok as a barrier for herpes simplex virus transmission in men and women Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.